Literature DB >> 25071090

Restoration of renal function does not correct impairment of uremic HDL properties.

Chantal Kopecky1, Michael Haidinger1, Ruth Birner-Grünberger2, Barbara Darnhofer3, Christopher C Kaltenecker1, Gunther Marsche4, Michael Holzer4, Thomas Weichhart5, Marlies Antlanger1, Johannes J Kovarik1, Johannes Werzowa1, Manfred Hecking1, Marcus D Säemann6.   

Abstract

Cardiovascular disease remains the leading cause of death in renal transplant recipients, but the underlying causative mechanisms for this important problem remain elusive. Recent work has indicated that qualitative alterations of HDL affect its functional and compositional properties in ESRD. Here, we systematically analyzed HDL from stable renal transplant recipients, according to graft function, and from patients with ESRD to determine whether structural and functional properties of HDL remain dysfunctional after renal transplantation. Cholesterol acceptor capacity and antioxidative activity, representing two key cardioprotective mechanisms of HDL, were profoundly suppressed in kidney transplant recipients independent of graft function and were comparable with levels in patients with ESRD. Using a mass spectroscopy approach, we identified specific remodeling of transplant HDL with highly enriched proteins, including α-1 microglobulin/bikunin precursor, pigment epithelium-derived factor, surfactant protein B, and serum amyloid A. In conclusion, this study demonstrates that HDL from kidney recipients is uniquely altered at the molecular and functional levels, indicating a direct pathologic role of HDL that could contribute to the substantial cardiovascular risk in the transplant population.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  CKD; cardiovascular disease; dyslipidemia; lipids; renal transplantation

Mesh:

Substances:

Year:  2014        PMID: 25071090      PMCID: PMC4341473          DOI: 10.1681/ASN.2013111219

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  53 in total

Review 1.  Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?

Authors:  Aneta Otocka-Kmiecik; Dimitri P Mikhailidis; Stephen J Nicholls; Michael Davidson; Jacek Rysz; Maciej Banach
Journal:  Prog Lipid Res       Date:  2012-05-15       Impact factor: 16.195

2.  Uremia alters HDL composition and function.

Authors:  Michael Holzer; Ruth Birner-Gruenberger; Tatjana Stojakovic; Dalia El-Gamal; Veronika Binder; Christian Wadsack; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2011-07-29       Impact factor: 10.121

Review 3.  Inflammation alters HDL composition and function: implications for HDL-raising therapies.

Authors:  Gunther Marsche; Marcus D Saemann; Akos Heinemann; Michael Holzer
Journal:  Pharmacol Ther       Date:  2012-12-14       Impact factor: 12.310

4.  HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction.

Authors:  Stephen Zewinger; Thimoteus Speer; Marcus E Kleber; Hubert Scharnagl; Rainer Woitas; Philipp M Lepper; Karolin Pfahler; Sarah Seiler; Gunnar H Heine; Winfried März; Günther Silbernagel; Danilo Fliser
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

Review 5.  Future therapeutic directions in reverse cholesterol transport.

Authors:  Amit V Khera; Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2010-01       Impact factor: 5.113

Review 6.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

Authors:  Robert S Rosenson; H Bryan Brewer; W Sean Davidson; Zahi A Fayad; Valentin Fuster; James Goldstein; Marc Hellerstein; Xian-Cheng Jiang; Michael C Phillips; Daniel J Rader; Alan T Remaley; George H Rothblat; Alan R Tall; Laurent Yvan-Charvet
Journal:  Circulation       Date:  2012-04-17       Impact factor: 29.690

Review 7.  Importance of high-density lipoprotein quality: evidence from chronic kidney disease.

Authors:  Valentina Kon; T Alp Ikizler; Sergio Fazio
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-05       Impact factor: 2.894

8.  Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.

Authors:  Bengt Fellström; Hallvard Holdaas; Alan G Jardine; Ingar Holme; Gudrun Nyberg; Per Fauchald; Carola Grönhagen-Riska; Søren Madsen; Hans-Hellmut Neumayer; Edward Cole; Bart Maes; Patrice Ambühl; Anders G Olsson; Anders Hartmann; John O Logan; Terje R Pedersen
Journal:  Kidney Int       Date:  2004-10       Impact factor: 10.612

9.  Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling.

Authors:  Meliana Riwanto; Lucia Rohrer; Bernd Roschitzki; Christian Besler; Pavani Mocharla; Maja Mueller; Damir Perisa; Kathrin Heinrich; Lukas Altwegg; Arnold von Eckardstein; Thomas F Lüscher; Ulf Landmesser
Journal:  Circulation       Date:  2013-01-24       Impact factor: 29.690

10.  Association of high-density lipoprotein cholesterol with the estimated glomerular filtration rate in a community-based population.

Authors:  Fan Wang; Jin Zheng; Ping Ye; Leiming Luo; Yongyi Bai; Ruyi Xu; Li Sheng; Tiehui Xiao; Hongmei Wu
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more
  24 in total

1.  HDL: Beyond Atheroprotection.

Authors:  Valentina Kon; MacRae F Linton
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

2.  HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients.

Authors:  Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Robin P F Dullaart; Jan-Stephan F Sanders; Stephan J L Bakker; Uwe J F Tietge
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

Review 3.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

4.  Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients.

Authors:  Yasunori Suematsu; Masaki Goto; Christina Park; Ane C F Nunes; WangHui Jing; Elani Streja; Connie M Rhee; Siobanth Cruz; Moti L Kashyap; Nosratola D Vaziri; Vasanthy Narayanaswami; Kamyar Kalantar-Zadeh; Hamid Moradi
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

5.  Kidney function is associated with an altered protein composition of high-density lipoprotein.

Authors:  Katya B Rubinow; Clark M Henderson; Cassianne Robinson-Cohen; Jonathan Himmelfarb; Ian H de Boer; Tomas Vaisar; Bryan Kestenbaum; Andrew N Hoofnagle
Journal:  Kidney Int       Date:  2017-07-26       Impact factor: 10.612

Review 6.  HDL in CKD-The Devil Is in the Detail.

Authors:  Florian Kronenberg
Journal:  J Am Soc Nephrol       Date:  2018-02-22       Impact factor: 10.121

7.  Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis.

Authors:  R Kaseda; Y Tsuchida; J L Gamboa; J Zhong; L Zhang; H Yang; A Dikalova; A Bian; S Davies; A F Fogo; M F Linton; N J Brown; T A Ikizler; V Kon
Journal:  Nutr Metab Cardiovasc Dis       Date:  2018-03-08       Impact factor: 4.222

Review 8.  Deepening our understanding of HDL proteome.

Authors:  Graziella Eliza Ronsein; Tomáš Vaisar
Journal:  Expert Rev Proteomics       Date:  2019-08-27       Impact factor: 3.940

Review 9.  Kidneys: key modulators of high-density lipoprotein levels and function.

Authors:  Haichun Yang; Agnes B Fogo; Valentina Kon
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-05       Impact factor: 2.894

Review 10.  Kidney as modulator and target of "good/bad" HDL.

Authors:  Jianyong Zhong; Haichun Yang; Valentina Kon
Journal:  Pediatr Nephrol       Date:  2018-10-05       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.